Health Impact of and Policy Regulations on Electronic Cigarettes

Hilton Y. Lam,1 Carlo Irwin A. Panelo,2 Ofelia P. Saniel,3 Carmelita C. Canila,4 Jonathan P. Guevarra,5 Ma-Ann M. Zarsuelo6 and Ma. Angelica Q. Castro6

1Institute of Health Policy and Development Studies, National Institutes of Health, University of the Philippines Manila
2Department of Clinical Epidemiology, College of Medicine, University of the Philippines Manila
3Department of Epidemiology and Biostatistics, College of Public Health, University of the Philippines Manila
4Department of Health Policy and Administration, College of Public Health, University of the Philippines Manila
5Department of Health Promotion and Education, College of Public Health, University of the Philippines Manila
6University of the Philippines Manila Health Policy Development Hub

ABSTRACT

Background. New findings on the detrimental health effects of electronic nicotine delivery system (ENDS)/electronic non-nicotine delivery system (ENNDS) confounds the “harm reduction” perspective of using it as an alternative to conventional cigarettes. In the Philippines, the pressing debate on its safety and efficacy had initiated actions from policy makers on legislative issues such as draft DOH Administrative Order, House Bill 4325 and House Bill 532.

Objective. The study aimed to craft an evidence-based policy position on the regulation of ENDS/ENNDS.

Method. Review of literature was conducted, and the proposed scope and measures on electronic cigarette regulation were compared with WHO Framework Convention on Tobacco Control (WHO-FCTC) and existing policies of US FDA regulations on ENDS. Further, UP Manila convened experts of various related fields for evidence-based review and discussion of policy issues to arrive at a consensus policy statement and recommendations.

Results. Findings showed that ENDS/ENNDS still need further research to have conclusive results on long term safety and efficacy as smoking cessation methods.

Conclusion. Regulations for tobacco control should be clear and supported with strict guidelines in manufacturing, distribution, advertisement, selling, and usage restrictions in public. With the current review, it is recommended that ENDS/ENNDS regulation be under the mandate of the FDA in alignment to WHO-FCTC and to engage different stakeholders from policy makers, implementers, and other involved organizations.

Key Words: Electronic nicotine delivery system (ENDS), Electronic non-nicotine delivery system (ENNDS), Regulation policies

INTRODUCTION

The proven detrimental health effects of tobacco smoking paved the way for electronic cigarettes (EC) to enter the market. Sale of EC started via online stores in China, and now major international tobacco companies have launched their own brands.1 Electronic cigarettes penetrated the European market in 2005 and had a sharp increase in annual demand owing to advertisements portraying EC as a healthy cigarette alternative and smoking cessation tool.2 The global market of Electronic Nicotine Delivery System (ENDS)/Electronic Non-Nicotine Delivery System (ENNDS) was estimated to be US$ 10 billion in 2015. Majority of sales (56%) was attributed to the United States of America, 12% to the United Kingdom, 7% each for China, France, and Germany, and 3% each for Italy
E-cigarettes

and Poland. Internet sales accounted for one-third of the worldwide market in 2014, with the largest market share in the regions of Latin America, Australasia, and Asia Pacific.3

In the Philippines, the increase of EC market is parallel with the pressing debate on its safety and efficacy, and thus requiring the attention of the Philippine Food and Drug Administration (FDA) and legislators. In April 2013, Philippine FDA Advisory No. 2013-008 warned that beneficial claims as well as possible health consequences from EC have not been established and needed further research.4 This stirred opposing views between health advocates and ENDS stakeholders including the Philippine E-cigarette Industry Association (PECIA) which is composed of manufacturers, store owners, and suppliers of ENDS and related products in the country with the aim to set forth best practice standards and serve as the self-regulatory body of this new market. With the growing concerns, the FDA conducted public hearings in July and December 2013 to discuss the views of the public and stakeholders. Towards the end of 2013, the Department of Health (DOH) drafted an Administrative Order (AO) on the Guidelines on the Regulation of Electronic Nicotine Delivery System (ENDS) or Electronic Cigarettes as a Manufactured Product. In 2016, House Bills 4325 and 532 were proposed in order to regulate EC. In 2017, the President issued Executive Order 26 imposing a nationwide ban on smoking, however, EC were excluded. The DOH Secretary explained that the inclusion of ENDS in the smoking ban will be considered when there is enough evidence and a recommendation from the WHO is issued.5

REVIEW OF LITERATURE

A. Description of ENDS/ENNDS

The World Health Organization Tobacco Free Initiative (WHO-TFI) defines EC as “devices that do not burn or use tobacco leaves but instead a solution that the user then inhales.” EC is the generic term used to include both ENDS and ENNDS. All ENDS/ENNDS heat a solution to create an aerosol which frequently contains flavorants, propylene glycol, or and glycerin. All ENDS contain nicotine but ENNDS do not.6

Consumer satisfaction of ENDS/ENNDS are said to be derived from its efficiency in mimicking the sensory feel of conventional smoking. This is directly affected by the choice of vapor liquid, puffing style, and the device’s capacity to aerosolize the liquid.1

B. Health impact

Since ENDS/ENNDS were only introduced to the market in 2006, only short to medium-term studies on its adverse effects are available. Evidences on long-term health effects remain lacking.

According to WHO-FCTC, using ENDS/ENNDS “produces aerosol that ordinarily includes glycols, aldehydes, volatile organic compounds (VOCs), polycyclic aromatic hydrocarbon (PAHs), tobacco-specific nitrosamines (TSNAs), metals, silicate particles, and other elements. Dicarbonyls (glyoxal, methylglyoxal, diacetyl) and hydroxycarbonyls (acetol) also are thought to be important compounds in the aerosol.” Most of these toxicants have known ranges of health consequences.7

A systematic review in 2016 shows that the safety of ENDS/ENNDS in the long-term is unknown. Although there were no reported serious adverse effects considered related to ENDS/ENNDS use, the most common adverse effects observed were irritation of the mouth and throat.8 However, another study reported negative effects from use or exposure to ENDS/ENNDS and refill fluid such as 1) systemic effects including respiratory, gastrointestinal, neurological, cardiovascular, and immune irritation and responses; 2) nicotine poisoning; and 3) mechanical injury.9

Nicotine

Nicotine is the addictive tobacco component that is already an established contributor in cardiovascular diseases and have an impact on cognitive performance.9,10 In terms of ENDS, several studies show large variability on nicotine concentrations across brands, labels, and cartridges. Some studies show that short-term use results to increased heart-rate and elevation of diastolic blood pressure, while other studies show otherwise.1 Caution must still be taken by vulnerable groups (i.e. children, adolescent, pregnant women, women of child-bearing age) from nicotine exposure due to potential long-term consequences in brain development.7

The increased potential for accidental poisoning can be attributed to the easy access and availability of refill juice with high nicotine content, lack of or inaccurate labeling, and different flavors including candy and confectionery-like aromas that appeal to children. The lack of regulation on ENDS places at risk not only adults but also children, who model the behavior of adults, and teenagers who tend to use ENDS for social status and social acceptance.10

Although nicotine is addictive and has a range of local irritant effects, it is not a carcinogen. Lung cancer arises primarily from exposure to carcinogens in tobacco smoke.11 However, it was identified in the WHO-FCTC (2016) that given the chemical compounds in the liquids for ENDS/ENNDS aerosol: 1) there is potential cytotoxicity of solutions on pregnant women; 2) solid evidence from different research methods are still needed to be certain on potential adverse health effects; and 3) there are no agreed upon tolerance limits for smoke constituents.3

Mechanical Injury

There are few case reports related to EC battery explosions leading to multiple injuries. There were two reported cases of corneal injury, one oral burn due to explosion while using EC, and one leg burn from spontaneous explosion while EC was not in use.9,12 While
there are no published studies from the Philippines, online media reported a case of EC explosion during a trial use in a store. The few reports may mask the significant public health risk since similar incidents continue to appear in online media reports in different countries. Therefore, the actual number of cases is probably much higher than those reported.

**Second-hand Smoke**

In a recent systematic review, it was found that the second-hand aerosol (SHA) from ENDS/ENNDS has the potential to lead to adverse health effects. SHA from ENDS aerosol contain lower levels of nicotine and toxicants, except for metals such as nickel and chromium, compared to second-hand smoke (SHS) from conventional burning cigarettes. However, compared to background air level, nicotine in SHA is found to be 10 to 115 times higher, acetaldehyde between two to eight times higher, and formaldehyde about 20% higher.3

The WHO-FCTC report in 2016 stated that “while some argue that exposure to SHA is unlikely to cause significant health risks, they concede that SHA can be deleterious to bystanders with some respiratory pre-conditions”. The substances from the emission also accumulate in indoor air and may lead to harmful second-hand exposure.4

**Efficacy on Smoking Cessation**

There is some evidence (low in GRADE System) that EC may help smokers to quit smoking in the long term compared to placebo EC.8 Electronic cigarettes address the behavioral aspects of smoking (holding cigarette, enjoyment of smoking, and puffing) more than nicotine patches and other behavioral support, hence, more effective in smoking cessation. However, a recent cross-sectional study shows that on a population level, EC were not effective in helping smokers quit smoking conventional cigarettes in EU (and Great Britain) as smokers are more likely to completely quit smoking conventional cigarettes (EU) or Electronic Cigarettes as a Manufactured Product (ENDS) or Electronic Cigarettes as a Manufactured Product in 201345; (4) US FDA regulations on ENDS5; (5) European Tobacco Products Directive (EU-TPD)56; and (6) World Health Organization Framework Convention on Tobacco Control (WHO-FCTC) 2016 regulation options on ENDS/ENNDS.

In the USA, the FDA has the authority to regulate all commercial processes of EC since they were classified as tobacco products since 2016. In contrast, the draft DOH AO classified EC as a medicinal product instead of as a tobacco product. On the other hand, House Bill 4325 only provided that the manufacture and distribution of EC will be regulated by the FDA, with the DOH as the implementing agency for rules and regulations.

**Quality Assurance**

Based on the draft DOH AO, guidelines on claiming beneficial effects (cessation aid, etc.), ingredients, and cartridge design shall be strictly implemented to ensure that products meet quality standards. WHO-FCTC added that toxicological compounds should be banned/restricted while electrical safety should be monitored. In the UK, regulation of ENDS/ENNDS is specific to the nicotine amount where cartridges containing 0-20mg/mlare under EU Tobacco Directive (EU-TPD) while cartridges with higher nicotine levels are regulated by the EU’s Medicines and Healthcare Products Regulatory Agency (MHRA).

**Manufacturing and Distributing**

The US FDA clearly specifies that all manufacturers, distributors, and retailers of EC and EC-related products are subject to regulation. This is not specified in the draft DOH AO since only the Certificate of Product Registration (CPR) and License to Operate (LTO) are mentioned. Meanwhile, House Bill 4325 only includes provisions on registration of manufacturers with no specific requirements for compliance. Nevertheless, both USA and Philippine FDA guidelines require the manufacturers to meet the standards of current Good Manufacturing Practice (cGMP).

**Selling and Advertising**

Parameters on prohibiting access to minors and clear bold health warning statements in EC packages and advertisement are mentioned in the US FDA guidelines on ENDS, Philippine House Bills 4325 and 532, EU-TPD, and WHO-FCTC. Furthermore, in the draft DOH AO, FDA is tasked to conduct post-market surveillance and regulate the advertisement, promotion of the product, and the marketing activities of the establishment after the CPR has been issued.

**Impacts on the Environment**

In the draft DOH AO, FDA will not allow the use of electronic cigarettes in public areas or in areas and facilities that prohibit smoking. In the UK, Public Health England (2016) published proposed set of guidelines for smoking in...
public places that are based on five principles: 1) make clear
distinction between vaping and smoking; 2) ensure policies
are informed by the evidence on health risks to bystanders;
3) identify and manage risks of uptake by children and
young people; 4) support smokers to stop smoking and stay
smoke-free; and 5) support compliance with smoke-free law
and policies.

Terms with Tobacco Industry
House Bill 532 prohibits sponsorship of any companies
engaged in production, manufacture, and distribution of
cigarette, tobacco, or electronic smoking devices in any
public or private events that includes advertisement or
promotion of such company. In addition to this, WHO-
FCTC includes stricter guidelines, further limiting the
participation and partnership of tobacco industry with other
stakeholders (public or private) and related activities with
the interest of promotion.
Levy and colleagues (2016) suggest discouraging
cigarette use but providing means for smokers to quit by
creating policies that aim to discourage use of vaporized
nicotine products (VNP) by never smokers, while
encouraging innovations in VNP products that are proven
to support smoking cessation as there is a “strong potential
for VNP use to improve population health by reducing or
displacing cigarette use in countries where cigarette use is
high and smokers are interested in quitting.”

METHODS
Review of literature was conducted, and the proposed
scope and measures on electronic cigarette regulation were
compared with WHO Framework Convention on Tobacco
Control (WHO-FCTC) and existing policies of US FDA
regulations on ENDS.
Further, UP Manila convened experts of various
related fields for evidence-based review and discussion
of policy issues to arrive at a consensus policy statement
and recommendations.

RESULTS AND DISCUSSION
Key findings from the current review shows that
ENDS/ENNDS are claimed to emit less toxic substances
compared to burning tobacco. However, the contents of
cartridges vary widely as do their potential health effects.
There are documented short term adverse effects on its
usage but long term safety and health risk studies are still
inconclusive. Evidences from studies in different countries
on the use of ENDS/ENNDS as a smoking-cessation
method remains limited and mixed. Aside from the posed
health risk among the users, another population of concern
are those exposed to second-hand aerosol, particularly the
vulnerable groups, and those with respiratory pre-conditions
who are potentially at risk.

With its increasing demand in the market, initiatives
from international organizations are establishing guidelines
on its regulation. Commitment on its safe and monitored
manufacturing, distribution, advertisement, and selling
are starting to be evident on the emerging and existing
regulatory government policies globally. Currently, regulatory
measures for ENDS/ENNDS vary across countries.

RECOMMENDATIONS
Given the evidence-based safety and health risks of
ENDS/ENNDS and the regulatory policies identified and
practiced across countries, the following are recommended:
1. The use of ENDS/ENNDS should be regulated in
terms of its manufacture, distribution, sale and use, and
even its advertisements.
2. Regulation of ENDS/ENNDS can be done under the
mandate of the FDA. For example, the use of ENDS
as a smoking cessation method should be done under
medical supervision only. Never smokers should not be
allowed to use ENDS/ENNDS.
3. Further research is needed to establish the long-term
safety and health effects of ENDS/ENNDS.
4. Implementing agency should revisit our country
commitment to the WHO- FCTC, to which we were a
signatory in 2006.
5. Government must require licenses for all suppliers and
manufacturers of ENDS within the country and utilize
e-commerce laws to regulate internet sales of ENDS.
6. Government should counter misleading information in
advertising and promotional materials in the internet
and other media by providing balanced information
and enforcing consumer protection laws.
7. Since the government has already implemented
graphic warnings in cigarettes, there must be safety
seals approved by the government. This is in recognition
of the fact that e-liquids are already widely available
in the market, including through online access. To
protect consumers and the public from exposure to
dangerous substances contained in ENDS/ENNDS,
the government should develop strict measures to limit
the availability of and require proper marking of any
liquid that contains propylene glycol, a key ingredient
in most e-liquids.
8. The government, to regulate ENDS/ENNDS, must
develop its capacity to test samples of a wide array of
e-liquids.
9. Prevent the proliferation of EC in different outlets/
stores by restricting access or accrediting/ licensing
retailers in addition to a rigorous approval process.
10. Engage civil society organizations in monitoring
ENDS/ENNDS in the market.
11. To be consistent with the country’s enforcement of No
Smoking in Public Places, the government must ban use
of e-cigarette in public places for the protection of the
general public, particularly, protection from second-hand smoke (particularly against particulate toxins that can enter the lungs) and prevention of further youth uptake.

12. There should be more focused research to improve ENDS/ENNDS as a smoking cessation tool for heavy smokers or smokers who wish to quit.

Acknowledgement
The authors express their sincere gratitude to the Office of the Chancellor of the University of the Philippines Manila and the National Institutes of Health for their support and wisdom in this endeavor.

Statement of Authorship
All authors have approved the final version submitted.

Author Disclosure
All the authors declared no conflicts of interest.

Funding Source
No external funding.

REFERENCES